Skip to main content

NICE IDs

07/08/2025
ID547: Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over
01/08/2025
ID6266: Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis
31/07/2025
ID6381: Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer
22/07/2025
ID2725: Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma
16/07/2025
ID6364: Tarlatamab for previously treated advanced small-cell lung cancer
15/07/2025
ID6462: Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen
14/07/2025
ID6237: Guselkumab for treating moderately to severely active ulcerative colitis
14/07/2025
ID6238: Guselkumab for previously treated moderately to severely active Crohn's disease
11/07/2025
ID3981: Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable
04/07/2025
ID6372: Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over
25/06/2025
ID6274: Fruquintinib for previously treated metastatic colorectal cancer
20/06/2025
ID6392: Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments
19/06/2025
ID6153: Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer
06/06/2025
ID6221: Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over
03/06/2025
ID6411: Dapagliflozin for treating chronic kidney disease
27/05/2025
ID6244: Mirikizumab for treating moderately to severely active Crohn's disease
23/05/2025
ID3949: Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
21/05/2025
ID6222: Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease
20/05/2025
ID6317: Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]
01/05/2025
ID6308: Sparsentan for treating primary IgA nephropathy
Follow AWTTC: